TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03228667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Avelumab + PD-L1 t-haNK
Description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Durvalumab + PD-L1 t-haNK
Description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Docetaxel + Pembrolizumab
Description: The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Docetaxel + Nivolumab
Description: The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
Study: NCT02421224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teammate
Description: Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teammate
Description: Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teammate
Description: Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Bonus
Description: If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Bonus
Description: If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^7 pfu /2mL administered in each deltoid
Study: NCT02222909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-developed IT intervention
Description: The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
Study: NCT03484156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Installation of 3PEGASE Sensor
Description: Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
Study: NCT04245332

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coconut oil
Description: Coconut oil (4g/d)
Study: NCT00529230

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A set of questionnaires regarding sexual function, physical and psychological symptoms.

Intervention type: OTHER
Intervention: Blood draws to assess gonadal function
Description: Testosterone, FSH, and LH levels at study onset.
Study: NCT00459875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT00510718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: MDV3100 daily until progression or dose-limiting toxicity
Study: NCT02584231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin
Description: One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin
Description: One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
Study: NCT02104596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xylitol
Study: NCT03851120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics and LC-PUFA (480 mg DHA)
Description: Probiotics and LC-PUFA (480 mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotics and control LC-PUFA (120 mg DHA)
Description: Placebo probiotics and control LC-PUFA (120 mg DHA)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial stimulation and healthy eating education
Description: Psychosocial stimulation and healthy eating education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation and healthy eating education
Description: Psychosocial stimulation and healthy eating education
Study: NCT03863470

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization intervention
Description: The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
Study: NCT01971749

Intervention type: PROCEDURE
Intervention: Coronary stent procedure (CSP)

Intervention type: PROCEDURE
Intervention: Coronary-artery bypass grafting (CABG)
Study: NCT01088165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment arm
Description: Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid esters treatment group
Description: First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow band UVB radiation
Description: No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Narrow band UVB radiation
Description: No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation
Study: NCT00027378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine (Prozac)
Description: fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Treatment As Usual
Description: placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
Study: NCT01255813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation (Sub-perception)
Description: Stimulation applied below the perception threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation (Full)
Description: Stimulation applied above the perception threshold

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No stimulation applied
Study: NCT02715882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03183323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
Study: NCT04644627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Topical gentamicin ointment on wounds once daily for 6 weeks
Study: NCT00617123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg
Description: Vorapaxar 2.5 mg oral tablet
Study: NCT04399473

Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education (PNE)
Description: Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
Study: NCT01087294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-chimeric-antigen-receptor-transduced T cells
Description: Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-chimeric-antigen-receptor-transduced T cells
Description: Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: Donors will undergo leukapheresis
Study: NCT04181060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT00693823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral-popliteal Bypass
Description: Surgical placement of a prosthetic graft in the thigh from the groin to the knee
Study: NCT00617123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral tablet
Study: NCT04181060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT02684760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
Study: NCT04181060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT02684760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
Study: NCT03634449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: i-gel is a supraglottic airway devices with a gastric suction channel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
Study: NCT00002862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perillyl alcohol
Study: NCT04350489

Intervention type: OTHER
Intervention: Non-surgical periodontal treatment
Description: Conventional non-surgical periodontal treatment were performed
Study: NCT04181060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT00693823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery
Description: Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
Study: NCT00885105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular
Study: NCT05792891

Intervention type: OTHER
Intervention: Collecting biological material from frail patients, with or without COVID-19
Description: The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.

Intervention type: OTHER
Intervention: Collecting biological material from frail patients, with or without COVID-19
Description: The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
Study: NCT02193282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00430690

Intervention type: PROCEDURE
Intervention: acoustic startle testing
Description: acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
Study: NCT04975126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CatInfo tool
Description: Presentation about cataract surgery
Study: NCT00430690

Intervention type: PROCEDURE
Intervention: acoustic startle testing
Description: acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes

Intervention type: PROCEDURE
Intervention: acoustic startle testing
Description: acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
Study: NCT01101646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
Study: NCT03018795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decontamination of implant surfaces
Description: Decontamination of implant surfaces in combination with regenerative surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decontamination of implant surfaces
Description: Decontamination of implant surfaces in combination with regenerative surgery
Study: NCT00998673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silica Gel Fiber
Description: Silica Gel Fiber (SGF) applications as required

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard-of-Care
Description: Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
Study: NCT02193282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT02629120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
Study: NCT00489424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Study: NCT02629120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
Study: NCT01101646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
Study: NCT02629120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood stem cells
Description: Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
Study: NCT03739814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV